134 related articles for article (PubMed ID: 22609886)
1. Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT.
Hudspeth MP; Heath TS; Chiuzan C; Garrett-Mayer E; Nista E; Burton L; Ragucci D
Bone Marrow Transplant; 2013 Jan; 48(1):46-9. PubMed ID: 22609886
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD.
Sugita J; Matsushita T; Kashiwazaki H; Kosugi M; Takahashi S; Wakasa K; Shiratori S; Ibata M; Shono Y; Shigematsu A; Obara M; Fujimoto K; Endo T; Nishio M; Kondo T; Hashino S; Tanaka J; Asaka M; Imamura M
Bone Marrow Transplant; 2012 Feb; 47(2):258-64. PubMed ID: 21423118
[TBL] [Abstract][Full Text] [Related]
3. Role of folinic acid in methotrexate-based prophylaxis of graft-versus-host disease following hematopoietic stem cell transplantation.
AlJohani NI
Hematology; 2021 Dec; 26(1):620-627. PubMed ID: 34411497
[TBL] [Abstract][Full Text] [Related]
4. Folinic acid after MTX as prophylaxis for GVHD in pediatric bone marrow transplantation.
Kodama Y; Fukano R; Noguchi M; Okamura J; Inagaki J
Int J Hematol; 2015 Jan; 101(1):92-8. PubMed ID: 25465913
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study.
Yeshurun M; Rozovski U; Pasvolsky O; Wolach O; Ram R; Amit O; Zuckerman T; Pek A; Rubinstein M; Sela-Navon M; Raanani P; Shargian-Alon L
Blood Adv; 2020 Aug; 4(16):3822-3828. PubMed ID: 32790844
[TBL] [Abstract][Full Text] [Related]
6. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A versus methotrexate, followed by rescue with folinic acid as prophylaxis of acute graft-versus-host disease after bone marrow transplantation.
Torres A; Martinez F; Gomez P; Herrera C; Rojas R; Gomez-Villagran JL; Garcia-Castellano JM; Velasco F; Andres P; Fornes G
Blut; 1989 Feb; 58(2):63-8. PubMed ID: 2645954
[TBL] [Abstract][Full Text] [Related]
8. Folinic acid administration following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand.
Bhurani D; Schifter M; Kerridge I
Bone Marrow Transplant; 2008 Oct; 42(8):547-50. PubMed ID: 18622418
[TBL] [Abstract][Full Text] [Related]
9. Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay.
Freyer CW; Gier S; Moyer ME; Berryman N; Carulli A; Ganetsky A; Timlin C; Babushok DV; Frey NV; Gill SI; Hexner EO; Loren AW; Mangan JK; Martin ME; McCurdy S; Perl AE; Smith J; Luger SM; Stadtmauer EA; Porter DL
Transplant Cell Ther; 2021 May; 27(5):431.e1-431.e8. PubMed ID: 33965188
[TBL] [Abstract][Full Text] [Related]
10. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
[TBL] [Abstract][Full Text] [Related]
11. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
[TBL] [Abstract][Full Text] [Related]
12. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM
Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
[TBL] [Abstract][Full Text] [Related]
13. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
Piñana JL; Valcárcel D; Fernández-Avilés F; Martino R; Rovira M; Barba P; Martínez C; Brunet S; Sureda A; Carreras E; Sierra J
Bone Marrow Transplant; 2010 Sep; 45(9):1449-56. PubMed ID: 20140024
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
Huang B; Lin X; Zhang Z; Zhang Y; Zheng Z; Zhong C; He X; Chen M
Transplantation; 2020 Feb; 104(2):428-436. PubMed ID: 31283681
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
Neumann F; Graef T; Tapprich C; Vaupel M; Steidl U; Germing U; Fenk R; Hinke A; Haas R; Kobbe G
Bone Marrow Transplant; 2005 Jun; 35(11):1089-93. PubMed ID: 15821769
[TBL] [Abstract][Full Text] [Related]
16. The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.
Yerushalmi R; Shem-Tov N; Danylesko I; Shouval R; Nagler A; Shimoni A
Am J Hematol; 2017 Mar; 92(3):259-268. PubMed ID: 28052467
[TBL] [Abstract][Full Text] [Related]
17. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
Russell JA; Woodman RC; Poon MC; Jones AR; Ruether BA
Bone Marrow Transplant; 1994 Sep; 14(3):397-401. PubMed ID: 7994261
[TBL] [Abstract][Full Text] [Related]
18. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.
Chao NJ; Snyder DS; Jain M; Wong RM; Niland JC; Negrin RS; Long GD; Hu WW; Stockerl-Goldstein KE; Johnston LJ; Amylon MD; Tierney DK; O'Donnell MR; Nademanee AP; Parker P; Stein A; Molina A; Fung H; Kashyap A; Kohler S; Spielberger R; Krishnan A; Rodriguez R; Forman SJ; Bluzme KG
Biol Blood Marrow Transplant; 2000; 6(3):254-61. PubMed ID: 10871150
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial.
Locatelli F; Bruno B; Zecca M; Van-Lint MT; McCann S; Arcese W; Dallorso S; Di Bartolomeo P; Fagioli F; Locasciulli A; Lawler M; Bacigalupo A
Blood; 2000 Sep; 96(5):1690-7. PubMed ID: 10961865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
